Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Absci Corp

$6.55 +2.34% NASDAQ: ABSI · 15-min delayed
  • VANCOUVER, Washington
  • Public · NASDAQ: ABSI
  • 140 employees
$997.8MMarket cap
$4.5MRevenue · FY2024
-$115.2MNet income
140Employees
ABSINASDAQ
2021IPO

About Absci Corp

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2024
$4.5M
Net income
-$115.2M
Total assets
$216.3M
Market cap
$997.8M
Operating margin
-4297.0%
Net margin
-4113.7%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$2.8M
Operating expenses
$123.1M
Operating income
-$120.3M
Income tax
$69.0K
Net income
-$115.2M
EPS (basic)
$-0.84
EPS (diluted)
$-0.84

Balance sheet

Total assets
$216.3M
Current assets
$149.6M
Total liabilities
$26.8M
Current liabilities
$22.8M
Shareholders’ equity
$189.4M

Cash flow

Operating cash flow
-$92.9M
Investing cash flow
-$50.2M
Financing cash flow
$105.9M
Net cash flow
-$37.1M

Statements via Polygon.io (SEC filings)

NASDAQ: ABSI
$6.55 +2.34%

15-minute delayed · data by Polygon.io

Past year

$2.30 $7.34

52-week range

Market cap
$997.8M
EPS (diluted)
$-0.84
Shares outstanding
152.3M
Open
Day range
Prev close
Volume
IPO date
Jul 22, 2021

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Reported a net loss of $115.2M in FY2024.
  • Revenue declined 41% from FY2021 to FY2025.
  • Trading 11% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Absci Corp.

Write a review
Newsroom

News about Absci Corp

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →